InvestorsHub Logo
Followers 2
Posts 1360
Boards Moderated 0
Alias Born 01/05/2018

Re: Cyosol post# 16160

Wednesday, 06/10/2020 8:59:20 AM

Wednesday, June 10, 2020 8:59:20 AM

Post# of 21540
Looks like the phase 3 trial will be using synthetic bryostatin, allowing them to apply for approval without having to run a bioequivalence trial first.

"This strategic partnership with BryoLogyx brings to Neurotrope the first fully synthetic, scalable source of Bryostatin-1, providing a clinical supply for the Company's planned Phase 3 study and a manufacturing alternative that delivers a dramatically superior cost of goods," stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News